{"id":62619,"date":"2026-04-08T20:32:18","date_gmt":"2026-04-08T12:32:18","guid":{"rendered":"https:\/\/flcube.com\/?p=62619"},"modified":"2026-04-08T20:32:20","modified_gmt":"2026-04-08T12:32:20","slug":"gsks-exdensur-secures-second-nmpa-approval-in-china-for-chronic-rhinosinusitis-with-nasal-polyps-expanding-type-2-inflammation-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62619","title":{"rendered":"GSK&#8217;s Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio"},"content":{"rendered":"\n<p><strong>GlaxoSmithKline plc (GSK, <a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE: GSK<\/a>)<\/strong> announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted approval for <strong>Exdensur (depemokimab)<\/strong> as an add-on maintenance treatment for <strong>chronic rhinosinusitis with nasal polyps (CRSwNP)<\/strong> in adult patients whose disease remains inadequately controlled despite systemic corticosteroids and\/or surgery. This marks the <strong>second NMPA approval<\/strong> for the ultra-long-acting biologic within weeks, following its late-March approval for severe eosinophilic asthma.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-timeline-amp-indications\">Regulatory Timeline &amp; Indications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>GlaxoSmithKline plc (GSK, NYSE: GSK)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Exdensur (depemokimab)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Ultra-long-acting interleukin-5 (IL-5) inhibitor<\/td><\/tr><tr><td><strong>First China Approval<\/strong><\/td><td>Late March 2026 \u2013 Severe eosinophilic asthma (adults\/adolescents \u226512 years)<\/td><\/tr><tr><td><strong>Second Approval<\/strong><\/td><td>April 2026 \u2013 CRSwNP (adults inadequately controlled by steroids\/surgery)<\/td><\/tr><tr><td><strong>Dosing Regimen<\/strong><\/td><td>Twice-yearly subcutaneous administration<\/td><\/tr><tr><td><strong>Key Differentiator<\/strong><\/td><td>First ultra-long-acting biologic specifically developed for type 2 inflammation-driven respiratory diseases<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-profile-amp-mechanism-of-action\">Clinical Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecular Innovation<\/strong>: Exdensur combines <strong>high affinity and high binding potency<\/strong> for interleukin-5 (IL-5) with an <strong>extended half-life<\/strong>, enabling unprecedented twice-yearly dosing frequency<\/li>\n\n\n\n<li><strong>Target Population<\/strong>: Adult CRSwNP patients who have failed to achieve adequate disease control with conventional therapies including systemic corticosteroids and surgical intervention<\/li>\n\n\n\n<li><strong>Therapeutic Approach<\/strong>: Administered as add-on therapy <strong>combined with intranasal corticosteroids<\/strong><\/li>\n\n\n\n<li><strong>Type 2 Inflammation Focus<\/strong>: Specifically engineered for diseases driven by eosinophilic inflammation pathways<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-strategy-amp-market-opportunity\">Commercial Strategy &amp; Market Opportunity<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-dual-indication-portfolio-approach\">Dual-Indication Portfolio Approach<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Severe Eosinophilic Asthma<\/strong>: Approved late March 2026 for maintenance treatment in adults and adolescents aged 12+<\/li>\n\n\n\n<li><strong>CRSwNP Expansion<\/strong>: April 2026 approval creates cross-indication prescribing opportunities for pulmonologists and ENT specialists<\/li>\n\n\n\n<li><strong>Shared Pathophysiology<\/strong>: Both indications target IL-5-driven eosinophilic inflammation, enabling unified clinical messaging<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-china-market-dynamics\">China Market Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CRSwNP Prevalence<\/strong>: Estimated 2-4% adult prevalence in China, representing 28-56 million potential patients<\/li>\n\n\n\n<li><strong>Treatment Gap<\/strong>: Significant unmet need among patients refractory to steroids and surgery<\/li>\n\n\n\n<li><strong>Pricing Premium<\/strong>: Ultra-long-acting profile supports premium pricing versus existing biologics requiring monthly or bi-monthly dosing<\/li>\n\n\n\n<li><strong>Reimbursement Strategy<\/strong>: GSK expected to pursue NRDL inclusion for both indications in 2027 negotiations<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Differentiation<\/strong>: Twice-yearly dosing represents significant advantage over competitors requiring more frequent administration<\/li>\n\n\n\n<li><strong>First-Mover Advantage<\/strong>: First ultra-long-acting biologic specifically developed for type 2 respiratory inflammation in China<\/li>\n\n\n\n<li><strong>Portfolio Synergy<\/strong>: Complements GSK&#8217;s broader respiratory franchise including Trelegy and Nucala<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rapid Regulatory Success<\/strong>: Two NMPA approvals within weeks demonstrates GSK&#8217;s regulatory execution capability in China&#8217;s evolving biologics landscape<\/li>\n\n\n\n<li><strong>Type 2 Inflammation Leadership<\/strong>: Positions GSK as a comprehensive provider across the spectrum of IL-5-driven respiratory diseases<\/li>\n\n\n\n<li><strong>Dosing Innovation<\/strong>: Extended half-life technology may set new standard for biologic convenience in chronic respiratory conditions<\/li>\n\n\n\n<li><strong>Revenue Trajectory<\/strong>: Dual indications could accelerate China revenue ramp, with analysts projecting peak sales of $300-500M annually by 2030<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial expectations. Actual results may differ due to risks including reimbursement decisions, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GlaxoSmithKline plc (GSK, NYSE: GSK) announced that China&#8217;s National Medical Products Administration (NMPA) has granted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":62621,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[278,184,914],"class_list":["post-62619","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GSK&#039;s Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GlaxoSmithKline plc (GSK, NYSE: GSK) announced that China&#039;s National Medical Products Administration (NMPA) has granted approval for Exdensur (depemokimab) as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients whose disease remains inadequately controlled despite systemic corticosteroids and\/or surgery. This marks the second NMPA approval for the ultra-long-acting biologic within weeks, following its late-March approval for severe eosinophilic asthma.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62619\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK&#039;s Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio\" \/>\n<meta property=\"og:description\" content=\"GlaxoSmithKline plc (GSK, NYSE: GSK) announced that China&#039;s National Medical Products Administration (NMPA) has granted approval for Exdensur (depemokimab) as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients whose disease remains inadequately controlled despite systemic corticosteroids and\/or surgery. This marks the second NMPA approval for the ultra-long-acting biologic within weeks, following its late-March approval for severe eosinophilic asthma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62619\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-08T12:32:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-08T12:32:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0801.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62619#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62619\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK&#8217;s Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio\",\"datePublished\":\"2026-04-08T12:32:18+00:00\",\"dateModified\":\"2026-04-08T12:32:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62619\"},\"wordCount\":467,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62619#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0801.webp\",\"keywords\":[\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62619#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62619\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62619\",\"name\":\"GSK's Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62619#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62619#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0801.webp\",\"datePublished\":\"2026-04-08T12:32:18+00:00\",\"dateModified\":\"2026-04-08T12:32:20+00:00\",\"description\":\"GlaxoSmithKline plc (GSK, NYSE: GSK) announced that China's National Medical Products Administration (NMPA) has granted approval for Exdensur (depemokimab) as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients whose disease remains inadequately controlled despite systemic corticosteroids and\\\/or surgery. This marks the second NMPA approval for the ultra-long-acting biologic within weeks, following its late-March approval for severe eosinophilic asthma.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62619#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62619\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62619#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0801.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0801.webp\",\"width\":1080,\"height\":608,\"caption\":\"GSK's Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62619#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK&#8217;s Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK's Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio - Insight, China&#039;s Pharmaceutical Industry","description":"GlaxoSmithKline plc (GSK, NYSE: GSK) announced that China's National Medical Products Administration (NMPA) has granted approval for Exdensur (depemokimab) as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients whose disease remains inadequately controlled despite systemic corticosteroids and\/or surgery. This marks the second NMPA approval for the ultra-long-acting biologic within weeks, following its late-March approval for severe eosinophilic asthma.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62619","og_locale":"en_US","og_type":"article","og_title":"GSK's Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio","og_description":"GlaxoSmithKline plc (GSK, NYSE: GSK) announced that China's National Medical Products Administration (NMPA) has granted approval for Exdensur (depemokimab) as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients whose disease remains inadequately controlled despite systemic corticosteroids and\/or surgery. This marks the second NMPA approval for the ultra-long-acting biologic within weeks, following its late-March approval for severe eosinophilic asthma.","og_url":"https:\/\/flcube.com\/?p=62619","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-08T12:32:18+00:00","article_modified_time":"2026-04-08T12:32:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0801.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62619#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62619"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK&#8217;s Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio","datePublished":"2026-04-08T12:32:18+00:00","dateModified":"2026-04-08T12:32:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62619"},"wordCount":467,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=62619#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0801.webp","keywords":["GlaxoSmithKline","GSK","NYSE: GSK"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62619#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62619","url":"https:\/\/flcube.com\/?p=62619","name":"GSK's Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=62619#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=62619#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0801.webp","datePublished":"2026-04-08T12:32:18+00:00","dateModified":"2026-04-08T12:32:20+00:00","description":"GlaxoSmithKline plc (GSK, NYSE: GSK) announced that China's National Medical Products Administration (NMPA) has granted approval for Exdensur (depemokimab) as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients whose disease remains inadequately controlled despite systemic corticosteroids and\/or surgery. This marks the second NMPA approval for the ultra-long-acting biologic within weeks, following its late-March approval for severe eosinophilic asthma.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62619#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62619"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=62619#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0801.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0801.webp","width":1080,"height":608,"caption":"GSK's Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62619#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK&#8217;s Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0801.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62619"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62619\/revisions"}],"predecessor-version":[{"id":62622,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62619\/revisions\/62622"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/62621"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}